US 12,006,501 B2
Composition of drug targets and method of using thereof
Xiaolu Huang, Shanghai (CN); Xiao Liang, Shanghai (CN); Qingfeng Li, Shanghai (CN); and Bangda Chai, Shanghai (CN)
Assigned to Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (CN)
Appl. No. 16/759,362
Filed by Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai (CN)
PCT Filed Dec. 13, 2017, PCT No. PCT/CN2017/115764
§ 371(c)(1), (2) Date Apr. 27, 2020,
PCT Pub. No. WO2019/080284, PCT Pub. Date May 2, 2019.
Claims priority of application No. 201711022580.4 (CN), filed on Oct. 27, 2017.
Prior Publication US 2023/0193276 A1, Jun. 22, 2023
Int. Cl. C12N 15/113 (2010.01); A61K 47/42 (2017.01); A61P 17/02 (2006.01)
CPC C12N 15/1137 (2013.01) [A61K 47/42 (2013.01); A61P 17/02 (2018.01); C12N 2310/14 (2013.01); C12N 2320/32 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A drug combination comprising siRNAs that target human or mouse FK506 binding protein 10 (FKBP10) and siRNAs that target human or mouse procollagen C-endopeptidase enhancer (PCOLCE) transcript,
wherein sequence of the siRNA for human FKBP10 mRNA are as follows:
sense strand: SEQ ID NO: 1, 5′-GAAGGAAGAUUAUCAUCCCUCCAUU-3′;
antisense strand: SEQ ID NO: 2, 5′-AAUGGAGGGAUGAUAAUCUUCCUUC-3′;
wherein sequence of the siRNA for mouse FKBP10 mRNA are as follows:
sense strand: SEQ ID NO: 3, 5′-CCACACCUACAAUACCUAUTT-3′;
antisense strand: SEQ ID NO: 4, 5′-AUAGGUAUUGUAGGUGUGGTT-3′;
wherein sequence of the siRNA for human PCOLCE mRNA are as follows:
sense strand: SEQ ID NO: 5, 5′-CCUUCCUCCAGAGAGCUUU-3′;
antisense strand: SEQ ID NO: 6, 5′-AAAGCUCUCUGGAGGAAGG-3′;
wherein sequence of the siRNA for mouse PCOLCE mRNA are as follows:
sense strand: SEQ ID NO: 7, 5′-CCUGGCAACCAAGUGACUU-3′;
antisense strand: SEQ ID NO: 8, 5′-AAGUCACUUGGUUGCCAGG-3′.